Abstract:Cardiac fibrosis is a major and complex pathophysiological process that ultimately culminates in cardiac dysfunction and heart failure. This phenomenon includes not only the replacement of the damaged tissue by a fibrotic scar produced by activated fibroblasts/myofibroblasts but also a spatiotemporal alteration of the structural, biochemical, and biomechanical parameters in the ventricular wall, eliciting a reactive remodeling process. Though mechanical stress, post-infarct homeostatic imbalances, and neurohormonal activation are classically attributed to cardiac fibrosis, emerging evidence that supports the roles of immune system modulation, inflammation, and metabolic dysregulation in the initiation and progression of cardiac fibrogenesis has been reported. Adaptive changes, immune cell phenoconversions, and metabolic shifts in the cardiac nonmyocyte population provide initial protection, but persistent altered metabolic demand eventually contributes to adverse remodeling of the heart. Altered energy metabolism, mitochondrial dysfunction, various immune cells, immune mediators, and cross-talks between the immune cells and cardiomyocytes play crucial roles in orchestrating the transdifferentiation of fibroblasts and ensuing fibrotic remodeling of the heart. Manipulation of the metabolic plasticity, fibroblast–myofibroblast transition, and modulation of the immune response may hold promise for favorably modulating the fibrotic response following different cardiovascular pathological processes. Although the immunologic and metabolic perspectives of fibrosis in the heart are being reported in the literature, they lack a comprehensive sketch bridging these two arenas and illustrating the synchrony between them. This review aims to provide a comprehensive overview of the intricate relationship between different cardiac immune cells and metabolic pathways as well as summarizes the current understanding of the involvement of immune–metabolic pathways in cardiac fibrosis and attempts to identify some of the previously unaddressed questions that require further investigation. Moreover, the potential therapeutic strategies and emerging pharmacological interventions, including immune and metabolic modulators, that show promise in preventing or attenuating cardiac fibrosis and restoring cardiac function will be discussed.

Cardiac Fibrosis: New Insights into the Pathogenesis

The Pathogenesis of Cardiac Fibrosis: A Review of Recent Progress

Cardiac fibrosis.

Extracellular matrix remodeling and cardiac fibrosis

Epigenetic Regulation of Fibroblasts and Crosstalk between Cardiomyocytes and Non-Myocyte Cells in Cardiac Fibrosis

Origins of cardiac fibroblasts

Endothelial Mesenchymal Transition in Cardiac Fibrosis

Origins of Cardiac Fibroblasts and Its Effects on Myocardial Fibrosis

Cardiac Fibrosis: Cellular Effectors, Molecular Pathways, and Exosomal Roles

Myocardial fibrosis in right heart dysfunction

Cardiac Fibrosis: Key Role of Integrins in Cardiac Homeostasis and Remodeling

Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies

Targeting Interactions between Fibroblasts and Macrophages to Treat Cardiac Fibrosis

Epigenetic signatures in cardiac fibrosis, special emphasis on DNA methylation and histone modification

Cardiac Fibrosis and Fibroblasts

Fibroblast Diversity and Epigenetic Regulation in Cardiac Fibrosis

Complex Relationship Between Cardiac Fibroblasts and Cardiomyocytes in Health and Disease

Current concepts in the epigenetic regulation of cardiac fibrosis

Proteomic Insights into Cardiac Fibrosis: from Pathophysiological Mechanisms to Therapeutic Opportunities

Cardiac fibrogenesis: an immuno-metabolic perspective

Myocardial fibrosis from the perspective of the extracellular matrix: mechanisms to clinical impact